1. Home
  2. Analysis
  3. Olmesartan-medoxomil

Olmesartan medoxomil: effectiveness, side effects, alternatives in the real world

Summary:

Olmesartan medoxomil: olmesartan medoxomil

We study 15,240 Olmesartan medoxomil users. The information eHealthMe analyzes includes:

- Effectiveness of Olmesartan medoxomil
- Alternative drugs to Olmesartan medoxomil
- Olmesartan medoxomil side effects and drug interactions

Number of reports submitted per year:

Olmesartan medoxomil: 15,240 reports from FDA and social media.

How effective is Olmesartan medoxomil?

Alternative drugs to the conditions Olmesartan medoxomil treats:

Olmesartan medoxomil side effects by duration, gender and age:

Browse all side effects of Olmesartan medoxomil:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Olmesartan medoxomil and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Compare Olmesartan medoxomil with similar drugs, by side effects and effectiveness:



Do you take Olmesartan medoxomil?

- You can use our AI tools to monitor drug safety and effectiveness.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

How we gather our data?

Healthcare data is obtained from a number of sources including the Food and Drug Administration (FDA). This information is aggregated and used to produce personalized reports that patients can reference. Browse all drugs on eHealthMe.

Recent studies on eHealthMe:

© 2026 eHealthMe.com. All rights reserved. Use of this site constitutes acceptance of eHealthMe.com's terms of service and privacy policy.